Browse Articles
Discover research articles across all indexed journals
Extracellular DNA in patients with urothelial carcinoma of the bladder.
834 Background: Higher concentration of extracellular DNA (ecDNA) in plasma of subjects with various cancers is associated with worse prognosis. The association of ecDNA and its subcellular origin – nuclear DNA (ncDNA) and mitochondrial DNA (mtDNA) with urothelial carcinoma of the bladder (BC) is unexplored. Deoxyribonuclease (DNase) can cleave ecDNA and modulate the observed association. The objective of this study was to identify the potential differences in ecDNA, ncDNA, mtDNA and DNase between patients with non-muscle-infiltrating BC (NMIBC) and muscle-infiltrating BC (MIBC) compared to controls. Methods: We analyzed a population of 62 individuals with BC (44 males, median age 67.5 years), 20 had Ta stage, 26 T1 stage (NMIBC) and 16 T2–T3 stage (MIBC). The control group consisted of 15 males and 6 females without history of cancer, median age 67.3 years. EcDNA was quantified fluorometrically after isolation from double centrifuged plasma. The subcellular origin of ecDNA was analyzed using quantitative real time PCR targeting specific nuclear and mitochondrial sequences. DNase activity was assessed using the single radial enzyme diffusion method. For statistical analysis, basic nonparametric tests were used. Results: In patients with BC compared to controls, we identified significantly higher ecDNA (median 15.0 v 11.7 ng/ml, P=.021) and ncDNA (median 4707 v 2136 GE/ml, P=.0046), but not mtDNA and DNase. Moreover, we determined a higher activity of DNase (median 2.3 vs 1.9 ng/ml, P=.0084) in subjects with NMIBC (Ta+T1) v MIBC. By mutual comparisons of all subgroups, following significant differences were recognized: ecDNA and ncDNA in MIBC v controls (P=.0065 and P=.0127, respectively) and DNase for Ta v MIBC (P=.0177). In addition, we detected a significant correlation on a stage of BC and rising ecDNA concentrations (P=.0076). Conclusions: In this study, we showed higher plasma ecDNA and ncDNA in patients with MIBC than controls and lower DNase activity in MIBC compared to NMIBC. The ecDNA concentrations increased with rising tumor stage. These results suggest a possible diagnostic and a likely prognostic value of ecDNA and DNase in BC. Further studies will focus on a potential association between plasma ecDNA and urinary ecDNA, which are assessed non-invasively and more frequently. This study was supported by the Ministry of Education, Science, Research and Sport of the Slovak Republic (grant number : VEGA 1/0090/22), the Slovak Research and Development Agency (grant number: APVV-22-0231) and OncoReSearch. Key Words: Bladder Cancer. Extracellular DNA. Nuclear DNA. Mitochondrial DNA. Nuclease.
A primary quantum current standard based on the Josephson and the quantum Hall effects
Racial differences in organic anion transport proteins (OATP) and outcome in castration resistant prostate cancer treated with AR pathway inhibitors in Alliance A031201: A phase III trial.
246 Background: Serum androgen levels are prognostic in mCRPC and genetic variation in androgen metabolism may drive these effects. OATPs, encoded by genes of the solute carrier organic anion (SLCO) family, govern the uptake of steroids. We hypothesize variation in androgen uptake may drive differential outcomes on ARPI therapy. A secondary analysis was the contribution of race to prevalence and outcome with the variants. Methods: A031201 was a randomized phase 3 trial in progressive mCRPC by Prostate Cancer Working Group 2 (PCWG2) criteria. Patients (pts) were randomized 1:1 to enzalutamide (ENZ) or ENZ plus abiraterone (AAP) at standard doses. Castrating therapy was maintained. The primary endpoint was overall survival (OS). Secondary endpoint was radiographic-free survival (rPFS). Germline DNA was genotyped for SLCO2B1 in 772 men from A031201 using a validated melting assay. 458 ENZ/AAP). Race is self-reported. Proportional hazards model was used to determine if variants predict OS/rPFS. Results: Two SLCO2B1 variants were analyzed (rs12422149 – GG (82% prevalence) vs AA allele (2% prevalence), and rs1789693 AA (prevalence 43%) vs TT allele (prevalence 13%). 105 (11%) Black patients were genotyped for rs1789693, prevalence of AA was 9%, with median rPFS 67 mos, OS of 67 mos; 50% had TT, median rPFS 16 mos (HR = 3.25 (95% CI 1.16-9.12) OS was 23 mos (hazard ratio for death 2.60 95% CI1.01-6.68). Hazard ratios for homo and heterozygotes are shown (Table). Conclusions: In black men, variations in OATP may contribute to differences in outcome when treated with ARPI therapy. Further study of these interactions with other factors is warranted. Clinical trial information: NCT01949337 . Outcome by genotype. Genotype Median in Months (95% CI) Hazard Ratio (95% CI) SLCO2B1_rs1789693 OS Black (n = 102)AA 67 (52, -) (n = 9)AT 36 (27, 53) (n = 42)TT 23 (20,42) (n = 51) Referent (ref)AT vs. AA 2.02 (0.78,5.26)TT vs. AA 2.60 (1.01, 6.68) White (n = 772; 5 undetermined (und))AA 35 (32-37) (n = 322)AT 36 (22, 39) (n = 346)TT 31 (27,43) (n = 99) RefAT vs. AA 1.01 (0.85,1.21)TT vs. AA 0.99(0.75-1.30) rPFS Black (n = 102)AA 67 (31, NR) (n = 9)AT 23 (17, 39) (n = 42)TT 16 (13,26) (n = 51) RefAT vs. AA 2.84 (1.00,8.07)TT vs. AA 3.25 (1.16, 9.12) White (n = 772; 5 und)AA 23 (20, 27) (n = 322)AT 23 (20, 25) (n = 346)TT 26 (17, 34) (n = 99) RefAT vs. AA 1.02 (0.86,1.21)TT vs. AA 0.85 (0.65, 1.12) SLCO2B1_rs12422149 OS Black (n = 102; 1 und)GG 36 (26,52) (n = 74)AG 26 (21, NR) (n = 27)AA NR (n = 0) RefAG vs GG 0.96 (0.56, 1.66)AA vs GG NE White (n = 772; 3 und)GG 34 (32,37) (n = 630)AG 36 (32, 44) (n = 125)AA 42 (25,NR) (n = 14) RefAG vs. GG 0.91 (0.72, 1.66)AA vs. GG 0.70 (0.35-1.41) rPFS Black (n = 102; 1 und)GG 23 (17,39) (n = 74)AG 20 (13, NR) (n = 27)AA NR (n = 0) RefAG vs GG 1.04 (0.61, 1.78) AA vs GG NE White (n = 772; 3 und)GG 23 (20,25) (n = 630)AG 22 (18, 26) (n = 125)AA 34 (14,NR) (n = 14) RefAG vs GG 1.07 (0.86, 1.3) AA vs. GG 0.63 (0.32,1.27) NR=not reached; NE= Not estimable.
Cabozantinib (C) ± atezolizumab (A) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Expansion cohorts from the open-label phase 1b COSMIC-021 study.
145 Background: The phase 3 CONTACT-02 study significantly improved PFS and showed a trend in OS benefit with C+A vs a second novel hormone therapy (NHT) in mCRPC pts with soft tissue metastases (mets). We report outcomes from similar pts in the randomized mCRPC expansion cohorts of COSMIC-021 evaluating the contribution of adding A to C vs C alone. Methods: Pts with mCRPC with extrapelvic visceral or nodal mets who progressed on one prior NHT were randomized to receive C (60 mg QD), A (1200 mg IV Q3W), or C (40 mg QD) + A (1200 mg IV Q3W). Cohort A (n=10) was terminated early (lacked objective responses). The primary and secondary endpoints were investigator-assessed ORR per RECIST v1.1 and safety, respectively. Efficacy outcomes by blinded independent radiology committee (BIRC) were also assessed. Flow cytometry and proteomic profiling were performed on baseline and on-treatment samples. Results: A total of 101 pts were randomized to C (n=51) and C+A (n=50); median age was 70 y in both groups, 75%/72% had bone mets, 20%/24% had liver mets, and 31%/24% received docetaxel for mCSPC. ORR by BIRC (Table) and investigator (C: 20%, 95% CI, 10–33; C+A: 22%, 95% CI, 12–36) were similar between groups. Although PFS by BIRC was similar (Table, HR, 0.96; 95% CI, 0.59–1.58), the KM estimate of pts without events at 12 mo was higher with C+A (25.8% vs 14.0%). Compared with C, C+A group had longer DOR (~2-fold), fewer pts with progressive disease (PD) as best response, a numerically higher median OS (HR, 0.91; 95% CI, 0.57–1.46), more pts with PSA response with longer duration of response (median mo [95% CI], NE [6.24, NE] vs 6.93 [4.63, NE]), and prolonged time to PSA progression (Table). In the liver mets subgroup, median PFS and OS were longer with C+A vs C (PFS: HR, 0.44; 95% CI, 0.15–1.34, 5.7 vs 2.5 mo; OS: HR, 0.25; 95% CI, 0.08–0.77, 14.7 vs 5.0 mo). Grade 3–4 treatment-related adverse events occurred in 51% and 58% in C and C+A, respectively; no grade 5 events occurred. Differential regulation of activated CD8 T cells, myeloid-derived suppressor cells, and immune response and apoptosis-related proteins were observed with C+A vs C or A. Conclusions: C and C+A demonstrated clinical activity in pts with mCRPC and extrapelvic soft tissue mets, with no new safety signals. These exploratory data from randomized cohorts suggest an additive effect of A to C with a prolonged DOR in C+A vs C; additive clinical benefits were noted in pts with liver mets. Clinical trial information: NCT03170960 . Efficacy outcomes by BIRC. C (n=51) C+A (n=50) ORR, % (95% CI) 12 (4–24) 14 (6–27) Complete / partial response, n (%) 0 / 6 (12) 0 / 7 (14) Stable disease / PD, n (%) 33 (65) / 9 (18) 31 (62) / 6 (12) DCR, n (%) 39 (76) 38 (76) Median DOR (95% CI), mo 4.3 (2.8–NE) 10.6 (6.7–NE) PSA response, n (%) 5 (12%) 8 (20%) Median time to PSA progression (95% CI), mo 3.5 (1.7–5.7) 5.6 (2.7–NE) Median PFS, mo 6.7 5.5 Median OS, mo 13.8 15.6 NE, not evaluable for KM estimates.
Real world comparison of time-to-next-treatment (TTNT), time-to-castration-resistance (TTCR), and overall survival (OS) among patients with <i>BRCA1/2</i> positive and homologous recombination repair (HRR) negative metastatic castration-sensitive prostate cancer (mCSPC).
77 Background: Patients with mCSPC harboring genetic alterations in HRR genes, particularly BRCA1/2 , may experience aggressive disease course and adverse clinical outcomes. This study compared real-world TTNT, TTCR, and OS between patients with BRCA1/2+ and HRR- mCSPC. Methods: Data from oncology centers included in the US-based Flatiron Health-Foundation Medicine, Inc. Metastatic PC Clinico-Genomic Database (1/1/2011–12/31/2022) were evaluated. Patients with mCSPC who received an HRR alteration test and initiated first-line (1L) treatment for mCSPC after 1/1/2018 (index date) were included. Patients with ≥1 positive test for BRCA1/2 ( BRCA1/2 +) and those with no positive test for any HRR alteration (HRR-; 8 alterations) were assessed for TTNT (time from index to start of subsequent treatment for PC), an indicator of clinical/non-clinical performance, TTCR (time from index to prostate-specific antigen increase on therapy or clinician documentation), and OS (time from initial PC diagnosis to death). Baseline characteristics (12 months pre-index) were balanced between cohorts using inverse-probability of treatment weighting. Outcomes between BRCA1/2+ and HRR- patients were compared using weighted Kaplan-Meier analyses. Hazard ratios (HRs), 95% confidence intervals (CIs) and nominal p-values were generated using weighted Cox proportional hazards models. Results: A total of 149 BRCA1/2+ and 1,042 HRR- patients with mCSPC were included. Weighted baseline characteristics were balanced. The median age was 70 years in both cohorts; 60.4% of BRCA1/2+ and 61.2% HRR- patients were White. Abiraterone acetate was most used in 1L ( BRCA1/2 +: 30.2%; HRR-: 30.7%). By 24 months after 1L initiation, a significantly higher proportion of BRCA1/2+ patients progressed to next treatment than HRR- patients (69.7% vs. 56.8%; HR: 1.45 [95% CI: 1.10, 1.92], p=0.009). Median TTNT was shorter in the BRCA1/2+ cohort (10.9 months) than HRR- cohort (18.7 months). By 24 months, a significantly higher proportion of BRCA1/2+ patients progressed to castration resistance than HRR- (72.2% vs. 61.4%; HR: 1.46 [95% CI: 1.16, 1.84], p=0.001). Median TTCR was shorter among the BRCA1/2 + cohort than HRR- cohort (12.9 months vs. 16.9 months). Numerically fewer BRCA1/2+ patients survived 24 months after PC diagnosis (80.6%) than the HRR- cohort (85.4%; HR: 1.46 [95% CI: 0.99, 2.14], p=0.054). Conclusions: This study demonstrates worse outcomes for patients with BRCA1/2+ mCSPC, particularly more rapid treatment changes and progression to mCRPC by 24 months. Given that BRCA1/2 alterations are the most prevalent HRR alterations observed in men with PC, these results support early identification and a need for more effective therapies for this population.
Cryo-EM structures of the BAF-Lamin A/C complex bound to nucleosomes
Abstract Barrier-to-autointegration factor (BAF) associates with mitotic chromosomes and promotes nuclear envelope assembly by recruiting proteins, such as Lamins, required for the reconstruction of the nuclear envelope and lamina. BAF also mediates chromatin anchoring to the nuclear lamina via Lamin A/C. However, the mechanism by which BAF and Lamin A/C bind chromatin and affect the chromatin organization remains elusive. Here we report the cryo-electron microscopy structures of BAF-Lamin A/C-nucleosome complexes. We find that the BAF dimer complexed with the Lamin A/C IgF domain occupies the nucleosomal dyad position, forming a tripartite nucleosomal DNA binding structure. We also show that the Lamin A/C Lys486 and His506 residues, which are reportedly mutated in lipodystrophy patients, directly contact the DNA at the nucleosomal dyad. Excess BAF-Lamin A/C complexes symmetrically bind other nucleosomal DNA sites and connect two BAF-Lamin A/C-nucleosome complexes. Although the linker histone H1 competes with BAF-Lamin A/C binding at the nucleosomal dyad region, the two BAF-Lamin A/C molecules still bridge two nucleosomes. These findings provide insights into the mechanism by which BAF, Lamin A/C, and/or histone H1 bind nucleosomes and influence chromatin organization within the nucleus.
Sociodemographic disparities in treatment (tx) patterns and clinical outcomes among real-world patients (pts) with locally advanced/metastatic urothelial carcinoma (la/mUC) in the US.
707 Background: Sociodemographic disparities in la/mUC pt population include worse survival outcomes observed among certain pt subgroups. This study evaluates disparities among la/mUC pts receiving systemic therapies overall and those initiating an antibody drug conjugate in the real world. Methods: This descriptive, retrospective cohort study used US Flatiron Health electronic health record–derived de-identified database. Pts aged ≥ 18 yrs were grouped into cohorts C1 (all pts with la/mUC) and C2 (2L+ sacituzumab govitecan [SG] or 1L+ enfortumab vedotin [EV]) with tx initiation on/after Jan 2017 and Dec 2019, respectively; data cutoff for both cohorts was July 2024. Pt demographics and clinical outcomes (overall survival [OS] and time to tx discontinuation [TTD]) were calculated overall and by race. Socioeconomic status (SES) index was calculated using Yost index score (1 = lowest category; 5 = highest). Predictors of survival were assessed using Cox proportional hazards model. Results: C1 comprised 5102 pts. Most were White (68%) followed by Other race (11%), Black (5%), and Asian (1%); 15% were missing race. The racial distribution among C2 (N = 767) was similar to C1. Median age across C1 and C2 was similar (74 and 73 yrs, respectively), with Black pts being the youngest in both cohorts (median ages in C1 and C2: 70 and 65 yrs, respectively). Across both cohorts, Black and Asian pts, respectively, had the greatest proportion of pts in the lowest SES index group (C1: 36.7% and 13.3%; C2: 43.6% and 22.2%). In C1, median TTD (95% CI) was 3.0 (2.8-3.0) mos and was similar across all races. In C2, median TTD was higher for Asian (6.8 [4.2-NR] mos) and Black pts (6.5 [2.3-8.1] mos) and lowest for Other race (3.1 [1.9-4.3] mos). Median OS (95% CI) was 13.3 (12.6-13.9) mos in C1 and 11.9 (10.4-12.9) mos in C2. In both C1 and C2, Asian pts had the longest survival (median OS: 25.2 [11.9-41.9] and 14.0 [9.3-NR] mos, respectively) and Black pts had the shortest survival (median OS: 11.2 [9.2-15.9] and 11.4 (6.9-20.5] mos, respectively). Exploratory Univariate Cox modeling (limited by small sample size) suggested older age, history of smoking, treatment in community setting, de novo metastatic diagnosis, and ECOG score ≥ 2 are factors associated with low survival in C1 and only history of smoking and ECOG score ≥ 2 in C2. Conclusions: In this real-world study of treated pts with la/mUC, sample sizes, especially in C2, further research is needed to understand disparities and pt-centric factors that may impact tx decisions, TTD patterns, and reasons for discontinuation to define and address the unmet medical needs of these pts.
Evaluation of de novo oligometastatic prostate cancer patients managed with radiation therapy: A multi-institution, real-world dataset.
113 Background: Oligometastatic prostate cancer (omPCa) is an understudied entity, historically defined as ≤5 non-visceral metastases. However, its true prevalence in the molecular diagnostic imaging (MDI) era is unknown. Therapeutic clinical trials in advanced PCa based on conventional imaging modalities (CIM) complicate the ability to extrapolate findings to omPCa. Consequently, there is not a standard treatment approach; radiation therapy (RT) recommendations can vary widely. We sought to evaluate management and outcomes of de novo omPCa patients treated with RT in a multi-institutional cohort. Methods: Patients presenting with de novo omPCa (≤5 non-visceral lesions, allowance for >5 per physician discretion) diagnosed via CIM and/or MDI across 7 participating institutions were identified. Demographic/clinical data were collected. Clinical outcomes, including disease progression (any biochemical recurrence or distant failure) and survival were assessed. Progression-free survival (PFS) and overall survival (OS) were determined using the Kaplan-Meier method. Results: 163 patients treated with RT between 2015-2024 were analyzed (clinical data at diagnosis; Table). Over half of patients (90/163, 55%) were diagnosed using MDI, the remainder via CIM. 7% of patients presented with pelvic lymph nodes (LNs) only, 2% with non-regional LNs, 42% with bone only disease, and the remainder with a combination. Most patients (161/163) received systemic therapy. Of 131 patients with details, 39% received androgen deprivation therapy (ADT) alone, the remainder received ADT + androgen receptor signaling inhibitor (n=51); 8 also received docetaxel. 4% of patients received prostate RT alone, 5% of patients received prostate + pelvic RT, 17% of patients received metastasis-directed RT only, 36% of patients received prostate + pelvic + metastasis-directed RT, and 38.7% of patients received prostate + metastasis-directed RT. 152 patients had full follow-up (FU) details available. Median FU from time of omPCa diagnosis was 31 months (range, 3-229). Twenty-two patients developed distant metastases (outside of documented OM). Five-year OS from time of diagnosis was 91% (95%CI 80,97). Five-year PFS after RT was 51% (95%CI 30,68) with median PFS of 74 months (95%CI 41, not reached). Conclusions: In this contemporary real-world cohort, nearly all patients with de novo omPCa received systemic therapy and ~75% were treated with at least prostate + metastasis-directed RT. Identification of omPCa included both MDI and CIM, reflecting real-world patterns. Further analysis incorporating additional institutions, oligorecurrent and oligoprogressive patients is ongoing, and will evaluate the association of treatment characteristics on progression at last FU. Characteristic Age Gleason score PSA Number of lesions Median, range 68 (44-92) 8 (6-10) 17 (2-2670) 2 (1-8)
Efficacy of targeted therapies (TT) after HIF-2⍺ inhibitor-based treatment in advanced renal cell carcinoma (aRCC).
508 Background: Hypoxia-inducible factor 2⍺ (HIF) inhibitors are active in renal cell carcinoma refractory to prior treatment with tyrosine kinase inhibitors (TKI) and immunotherapy, including anti-PD-1 monotherapy or combinations with anti-CTLA-4, and represent a new therapeutic option. However, the efficacy of TT after HIF-2⍺ inhibitors has not been assessed. Methods: A retrospective review of medical records from aRCC patients (pts) treated with HIF-2a inhibitors at five academic institutions was conducted. Pts who received subsequent treatment with TT were identified to collect outcomes in terms of best radiological response by RECIST 1.1 criteria (BRR), time to treatment failure (TTF), defined as treatment failure can be defined as one or a combination of events, including disease progression, discontinuation of treatment due to toxicity, or death from any cause; and overall survival (OS). This work was approved by an ethics board and all patients provided approval. Results: Data of 35 pts were available: 30 (85%) were male and 18 (51%) were metastatic at diagnosis. IMDC risk group was favorable, intermediate and poor in 11 (31%), 20 (57%) and 4 (11%) pts, respectively. Belzutifan was administered as monotherapy in 27 (77%) and in combination in 8 (22%) pts. Regarding first subsequent TT, 30 (85%) received TKI and 5 (14%) received mammalian target of rapamycin (mTOR). TT post HIF-2a was administered as second-line, third-line, fourth-line and beyond fourth-line in 3 (8%), 4 (9%), 18 (51%) and 10 (28%) pts, respectively. Treatment was interrupted due to progression in 28 (80%), 1 (3%) discontinued due to toxicity and 7 (20%) remained on treatment after data cut-off. Median follow-up was was 19 months.Median TTF on subsequent TT was 5.74 months (95% CI: 2.82–8.00). Median OS was 10,49 months (95% CI: 6,13-NR) with 17% pts alive at 1 year from the initiation of subsequent TT. Investigator-assessed BRR to subsequent TT was available for 33 out of 35 pts. Partial response and stable disease were observed in 7 (20%) and 12 (34%), respectively. Progressive disease was observed in 14 (40%) pts. Conclusions: Both VEGF/VEGFR and mTOR inhibitors have activity following HIF-2α blockade. However, 40% of patients will be refractory to treatment. This highlights the need for new drugs with distinct mechanisms of action.
Loss-of-function mutations in the dystonia gene THAP1 impair proteasome function by inhibiting PSMB5 expression
Abstract The 26S proteasome is a multi-catalytic protease that serves as the endpoint for protein degradation via the ubiquitin-proteasome system. Proteasome function requires the concerted activity of 33 distinct gene products, but how the expression of proteasome subunits is regulated in mammalian cells remains poorly understood. Leveraging coessentiality data from the DepMap project, here we characterize an essential role for the dystonia gene THAP1 in maintaining the basal expression of PSMB5 . PSMB5 insufficiency resulting from loss of THAP1 leads to defects in proteasome assembly, impaired proteostasis and cell death. Exploiting the fact that the toxicity associated with loss of THAP1 can be rescued upon exogenous expression of PSMB5, we define the transcriptional targets of THAP1 through RNA-seq analysis and perform a deep mutational scan to systematically assess the function of thousands of single amino acid THAP1 variants. Altogether, these data identify THAP1 as a critical regulator of proteasome function and suggest that aberrant proteostasis may contribute to the pathogenesis of THAP1 dystonia.
Real-world analysis of the efficacy and safety of enfortumab vedotin in patients with locally advanced or metastatic urothelial carcinoma: A multicenter retrospective study.
712 Background: We investigated the efficacy and safety enfortumab vedotin (EV) in patients with locally advanced or metastatic urothelial carcinoma in real-world practice. Methods: This multicenter retrospective study included 419 patients treated for locally advanced or metastatic urothelial carcinoma between April 2004 to April 2024. The patients were categorized into the following three groups: 87 patients who underwent first-line chemotherapy and sequential chemotherapy alone (chemo-alone group), 217 patients who underwent maintenance immunotherapy or second-line immunotherapy after first-line chemotherapy (chemo-ICI group) and 115 patients who were treated with EV after first-line chemotherapy and immunotherapy (chemo-ICI-EV group). The primary outcome was the comparison of progression-free survival (PFS) of first-line therapy and overall survival (OS) from first-line therapy between the three treatment groups. Secondary outcomes included the efficacy and safety in the chemo-ICI-EV group focusing on skin adverse events (AEs). Results: The OS from first-line therapy was significantly longer in the chemo-ICI-EV group than that in the other groups. There was no significant difference in the first-line PFS of first-line therapy between the three groups. A multivariable Cox regression analysis showed the administration of EV was significantly associated with prolonged OS. Skin AEs were observed in 69 (60%) as a major adverse event. The PFS and OS in the patients with skin AEs was significantly longer than in the patients without skin AEs despite the reduced dose of EV. A multivariable Cox regression analysis showed that skin AEs were significantly associated with prolonged RFS and OS. Conclusions: The administration of EV significantly improved oncological outcomes in the real-world practice. Dose adjustment of EV may be key for long-term use and oncological outcomes.
Patient-reported outcomes (PROs) for tivozanib (TIVO) + nivolumab (NIVO) vs TIVO monotherapy in patients with renal cell carcinoma (RCC) following an immune checkpoint inhibitor (ICI): Results of the phase 3 TiNivo-2 study.
459 Background: The TiNivo-2 study assessed TIVO 0.89 mg + NIVO vs TIVO 1.34 mg in patients with RCC that progressed after ICI therapy. This study did not meet its primary endpoint of demonstrating a benefit of adding NIVO to TIVO vs TIVO after prior ICI exposure; however, clinically meaningful outcomes were observed with TIVO as a second-line (2L) and third-line (3L) treatment following ICI. In the intent-to-treat population, the median progression-free survival was 5.7 months (95% CI, 4.0-7.4) with TIVO + NIVO and 7.4 months (5.6-9.2) with TIVO (hazard ratio, 1.10; 95% CI, 0.84-1.43; P =.49), with fewer treatment-emergent adverse events in the TIVO + NIVO vs TIVO arm. Quality of life (QOL) data are reported here (NCT04987203). Methods: The Functional Assessment of Cancer Therapy Kidney Cancer Symptom Index–Disease-Related Symptoms (FKSI-DRS) and European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 questionnaires were administered at baseline (BL), day 1 of each cycle, and end of treatment. The PRO-evaluable set was defined as all randomized patients with a BL and ≥1 post-BL assessment. Descriptive statistics were provided for the FKSI-DRS and EORTC QLQ-C30 data. The number and percentage of patients categorized as having improved (I), stable (S), or deteriorated (D) QOL were summarized. Results: As of April 1, 2024, median follow-up was 12.0 months. Median duration (range) of treatment was 6·3 months (2.68-10.12) with TIVO + NIVO and 7·4 months (2.83-11.04) with TIVO. Completion rates for FKSI-DRS and EORTC QLQ-C30 were >90% at BL and >50% at week 24 (≈6 mo.) in each arm. Compliance rates for both instruments at BL and week 24 were >90%. PRO results are presented in the table. Conclusions: There were no differences in the PRO outcomes between the combination therapy and monotherapy arms or between the 2 different TIVO doses. PRO data suggested that TIVO maintained the FKSI-DRS and EORTC QLQ-C30 mean scores from BL to week 24. In the TIVO arm, the proportion of patients who had improvement in FKSI-DRS and EORTC QLQ-C30 scores was numerically better in patients receiving 2L vs 3L treatment, while the portion of patients with a deterioration was smaller in the 2L than in the 3L. Clinical trial information: NCT04987203 . PRO variables TIVO + NIVO TIVO ITT 2L 3L ITT 2L 3L FKSI-DRSBL mean (SD) 28.8 (5.6) 29.5 (4.9) 27.6 (6.5) 29.3 (5.3) 29.1(5.5) 29.5 (5.0) Week 24 mean (SD) 29.9 (4.9) 30.1 (4.7) 29.5 (5.4) 29.4 (5.3) 29.3 (4.8) 29.6 (6.3) I/S/D, % 28.2/47.2/24.6 28.0/52.7/19.4 28.6/36.7/34.7 22.9/53.5/23.6 27.5/53.8/18.7 15.1/52.8/32.1 EORTC-QLQ-C30BL mean (SD) 63.4 (23.4) 65.0 (21.8) 60.5 (26.1) 66.2 (21.4) 67.1 (21.9) 64.9 (20.7) Week 24 mean (SD) 68.7 (17.4) 68.7 (16.1) 68.6 (20.6) 64.8 (21.1) 64.6 (20.7) 65.1 (22.4) I/S/D, % 27.7/48.9/23.4 27.8/52.2/20.0 27.7/42.6/29.8 21.3/53.7/25.0 23.0/56.3/20.7 18.4/49.0/32.7
Global, phase 3, open-label, single arm studies to evaluate the efficacy, safety, and pharmacokinetics of FP-014, 11.25 mg (triptorelin mesylate injection, 11.25 mg) and FP-014, 22.5 mg (triptorelin mesylate injection, 22.5 mg) in patients with advanced prostate cancer.
TPS284 Background: When given continuously, long-acting LH-RH agonist triptorelin is known to inhibit pituitary gonadotropin secretion and suppress testicular and ovarian steroidogenesis. Serum testosterone concentrations in males have been reduced to levels associated with castration (< 50 ng/dL in serum). This effect is generally observed within two to four weeks after the start of treatment and is maintained as long as treatment continues. Induction and maintenance of castrate levels of serum testosterone concentrations in prostate cancer patients is a standard palliative treatment and slows cancer cell growth. FP-014 was formulated in N-methyl-2-pyrrolidone (NMP) and poly (D, L-lactide-co-glycolide) (PLGA) to control and sustain the release of bioactive triptorelin after subcutaneous administration. Two dosages of FP-014 are under investigation: 11.25 mg for three-month release, and 22.5 mg for six-month release. Methods: The FP-014 11.25 mg three-month formulation study and FP-014 22.5 mg six-month formulation study are designed for six months and 12 months, respectively, to evaluate the safety, efficacy, and pharmacokinetics of subcutaneously administered FP-014 (triptorelin mesylate) in subjects with advanced prostate cancer who are candidates for androgen ablation therapy. Subjects will receive up to 2 doses of long-acting FP-014 every three months with the 11.25 mg formulation or every six months with the 22.5 mg formulation. Results: Primary endpoints: 1. The percentage of patients with a serum testosterone concentration suppressed to castrate levels (< 50 ng/dL) by Week 4 following the first SC injection of FP-. 2. The percentage of patients with serum testosterone concentration suppressed to castrate levels (< 50 ng/dL) from Week 4 through Week 24 (11.25 mg formulation) or Week 48 (22.5 mg formulation). Secondary endpoints: 1. Mean acute-on-chronic changes in serum testosterone and LH levels prior to the second injection through 48-72 hours after the second injection of FP-014. 2. Mean change in serum LH levels. 3. Mean change in serum PSA levels. 4. The percentage of patients with: PSA relapse (defined as an increase in serum PSA of > 50% PSA nadir) by End of Study after achieving serum PSA level ≤ 4 ng/mL post administration of FP-014; within normal limit serum PSA level (< 4 ng/mL) by End of Study; the percentage of patients with enhanced serum testosterone concentration suppression to < 20 ng/dL at Week 4 and at End of Study; and urinary signs and symptoms as assessed by International Prostate Symptom Score (I-PSS). Conclusion: Two Phase 3 studies are designed to evaluate the safety, efficacy, and pharmacokinetics of long-acting injectable FP-014 (triptorelin mesylate), aiming to demonstrate an alternative therapeutic option for patients with prostate cancer. Clinical trial information: TBD.
Long-read sequencing of 945 Han individuals identifies structural variants associated with phenotypic diversity and disease susceptibility
Prostate cancer liver metastases: Genomic profiling and clinical outcomes.
189 Background: Patients (pts) with metastatic prostate cancer and liver metastases have poor prognosis, but clinicogenomic analyses are limited. We examined the clinical and genomic features of a cohort with prostate cancer liver metastases (PCLM). Methods: Pts were identified from a prospective population-based biobank in British Columbia, Canada. Eligible pts had PCLM identified on imaging prior to any line of treatment. We collated clinical outcomes with cell-free DNA (cfDNA) sequencing results including circulating tumor DNA fraction (ctDNA%) and genomic alterations. Results: 2048 metastatic prostate cancer pts were enrolled from October 2016 to July 2024, of whom 1258 had sufficient clinical annotation to evaluate PCLM status. Of these, 167 (13%) were diagnosed with PCLM: 36 (22%) with castration-sensitive prostate cancer (mCSPC), 48 (29%) prior to first-line castration-resistant prostate cancer treatment (1L mCRPC), 30 (18%) prior to 2L mCRPC, and 53 (32%) prior to ≥3L mCRPC. Median follow-up was 60.3 months. Median age at metastatic diagnosis was 68.7 (IQR 61.8-74.7) years, 93 (56%) had de novo metastatic disease, 20 (12%) had histologically proven small cell carcinoma, 27 (16%) had low PSA (<5ng/mL) at baseline, and 111 (66%) had ≥3 liver metastases. For mCSPC pts, 27 (75%) received treatment intensification beyond ADT alone, including 5 (14%) with platinum chemotherapy. Median overall survival (mOS) for mCSPC pts was 15.5 months (95% CI 11.7-28.1), and median time to castration resistance was 8.1 months (95% CI 5.7-10.7). For mCRPC pts, 94 (72%) had prior exposure to ARPI, 56 (43%) to taxane, and 8 (6%) to platinum. mOS for 1L mCRPC pts was 9.4 months (95% CI 6.7-12.6), for 2L mCRPC 4.9 months (95% CI 3.5-9.7) and for ≥3L mCRPC 5.6 months (95% CI 4.1-8.4). For 134 pts with cfDNA results the median ctDNA% was 24.7 (IQR 4.6-53.9). Alterations were found in TP53 (47%), PTEN (26%), RB1 (19%), with 82 pts (61%) having alterations in at least one tumor suppressor gene (TSG) and 34 (25%) in more than one TSG. 14 pts (10%) had a BRCA2 alteration. ctDNA% and detectable TSG alterations were associated with survival of pts with PCLM (Table). Of 17 long survivors (pts who lived >24 months from start of next line treatment), 12 had cfDNA results available, median ctDNA% was 13.6%, and only 1 had TSG loss detected ( PTEN ). Conclusions: Pts with PCLM exhibit poor clinical outcomes; both elevated ctDNA% and TSG loss correlate with reduced overall survival. mCSPCmOS (months)N = 24 pts with cfDNA 1L mCRPCmOS (months) N = 35 pts with cfDNA 2L mCRPCmOS (months)N = 25 pts with cfDNA TSG status No alteration detected 57 23.6 8 Alteration detected 11.7 6.8 4.3 Univariable HR (95% CI) 9.3 (2.0-42.7)p<0.01 5.6 (2.1-15.5)p<0.01 1.4 (0.6-3.2)p=0.4 ctDNA% ≤ median ctDNA% (24.7%) 57 18.1 9 > median ctDNA% (24.7%) 14.7 5.8 12 Univariable HR (95% CI) 2.4 (1.0-5.4)p<0.05 2.7 (1.5-5.0)p<0.01 1.1 (0.6-2.0)p=0.8
The prognostic value of LDH in patients with good risk metastatic seminoma treated with single agent carboplatin AUC10.
644 Background: Raised lactate dehydrogenase (LDH) is a surrogate marker for disease burden and an independent adverse prognostic factor for IGCCCG good risk metastatic seminoma patients treated with cisplatin and etoposide-based chemotherapy (Beyer et al, 2021). Patients with a pre-treatment LDH greater than 2.5x the upper limit of normal (ULN), despite still categorized as good risk disease, have a poorer 3-year progression free survival (PFS) of 80% with this combination treatment. Carboplatin Area Under the Curve (AUC) 10 monotherapy is an alternative to cisplatin and etoposide-based chemotherapy, with comparable effectiveness and a better side effect profile. However, the prognostic value of LDH and specific outcomes of patients with raised LDH in patients treated with carboplatin AUC10 has not been evaluated. Methods: A retrospective analysis of outcomes of good risk metastatic seminoma patients treated with carboplatin AUC10 from January 2000 to January 2021 at two supra-regional cancer centres was conducted. Data were extracted using electronic health records. The variables collected included primary tumor location, stage, tumor markers, relapse date, post-relapse treatment and cause of death. Results: 245 patients were identified with a median follow up period of 5.9 years. The primary site of the tumor was most commonly the testes (n=229, 93.5%). 76 (31%) presented with stage 2a, 81 (33%) with stage 2b and 43 (16%) with stage 2c. 14 patients (6%) experienced a relapse, with 11 patients received bleomycin, etoposide and cisplatin as salvage treatment. 24 patients (10%) had LDH levels >2.5 ULN. The 3-year PFS rate for patients with LDH >2.5 ULN was 79.2% versus 95% in LDH <2.5 ULN (p=0.0004). This was comparable to the 80% reported in the high LDH group by Beyer et al. Conclusions: Our results confirm the validity of raised LDH as an adverse prognostic factor in good risk metastatic seminoma patients treated with carboplatin AUC10, with similar PFS outcomes compared to etoposide-cisplatin based chemotherapy described in Beyer et al. Elevated LDH does not appear to be a contraindication to the use of carboplatin AUC10 monotherapy in this patient population and represents a less toxic alternative to etoposide-cisplatin based chemotherapy.
Efficacy and safety of lenvatinib plus everolimus in metastatic renal cell carcinoma after immune checkpoint and VEGFR tyrosine kinase inhibitors.
489 Background: Limited studies have investigated the real-world effectiveness and safety of Lenvatinib (LEN) combined with everolimus (EVE) in metastatic renal cell carcinoma (mRCC), particularly after failure of immune checkpoint inhibitors (ICIs) and VEGFR tyrosine kinase inhibitors (TKIs). This study aimed to evaluate the efficacy and safety of LEN plus EVE in patients who had progressed after these prior therapies. Methods: This single-center retrospective study included mRCC patients at Asan Medical Center, Korea, who initiated LEN plus EVE as second-line or later therapy between September 2017 and June 2024. We reviewed electronic medical records for dosage, dose reductions, discontinuation, response, progression, and survival outcomes. The primary objectives were objective response rate (ORR) and progression-free survival (PFS), with secondary objectives including overall survival (OS), adverse events, and prognostic factors. Results: Eighty-two eligible patients were included, predominantly with clear cell type (n=74, 90.2%). ECOG performance status was 1 in 54 patients, and 2 in 26. At treatment initiation, the IMDC risk distribution was favorable (n=6, 7.3%), intermediate (n=48, 58.5%), and poor (n=28, 34.1%). The median number of prior therapies was four (range, 1-7), with 80.5% receiving LEN plus EVE as fourth-line or later therapy. All patients had prior anti-angiogenic TKI exposure, 86.6% had been treated with ICIs, and 37.8% had prior mTOR inhibitor therapy. The ORR was 39.0% (n=32/82), with a disease control rate (DCR) of 81.7% (n=67/82). The median follow-up duration was 21.8 months. The median time to progression (TTP) was 6.4 months (95% Confidence Interval [CI], 5.4-9.7), while the median PFS was 5.4 months (95% CI, 4.3-6.4), and the median OS was 7.7 months (95% CI, 6.2-12.1). Subgroup analyses indicated comparable ORR and PFS for patients treated beyond the fourth line (ORR 36.4%, PFS 5.3 months), those previously exposed to mTOR inhibitors (ORR 29.0%, PFS 5.5 months), and those who had progressed after both ICI and TKIs (ORR 38.0%, PFS 5.3 months). The median treatment duration was 6.8 months. Adverse events were significant: 54.9% required dose reductions of LEN, and 25.6% experienced treatment interruptions. For EVE, 17.1% required dose reductions, and 25.6% had interruptions due to toxicities. Notably, 31 patients (37.8%) developed proteinuria, with 18 experiencing grade 3 or higher. Conclusions: LEN plus EVE shows promising efficacy and disease control in heavily pretreated mRCC patients after failure of ICIs and VEGFR TKIs, even beyond the fourth line and in those previously treated with mTOR inhibitors. The safety profile aligns with known adverse effects, but the high incidence of proteinuria is notable. Further studies are warranted to optimize treatment protocols in this patient population.
Stepwise amplification of circularly polarized luminescence in indium-based metal halides by regulating their structural dimension
How unfavorable is AUA unfavorable intermediate-risk prostate cancer? Results from a large, institutional cohort.
342 Background: Major clinical guidelines including the American Urology Association (AUA) defines unfavorable intermediate-risk prostate cancer (UIR-PCa) according to diagnostic PSA, clinical stage, biopsy positive cores, and Gleason grade group (GG). The current AUA guidelines separate patients into 3 primary groups: 1) GG1 with PSA 10-20 and stage T2b-c, 2) GG2 with PSA 10-20 and/or stage T2b-c and/or ≥50% biopsy cores positive, and 3) GG3 with PSA <20. We sought to utilize a large institutional radical prostatectomy (RP) cohort with long-term outcomes data to determine how UIR-PCa has evolved over time, and whether the current groupings are equally unfavorable as defined by the current guidelines. Methods: Participants were diagnosed with UIR-PCa at University of California, San Francisco in 2000-2024 and underwent RP. Disease risk was defined by clinical Cancer of the Prostate Risk Assessment (CAPRA) at diagnosis and post-surgical CAPRA (CAPRA-S) at RP. Lifetable estimates, Kaplan-Meier curves, and Cox proportional hazards regression were performed to evaluate outcomes of recurrence, defined as either biochemical failure (two PSA ≥0.2 ng/ml) or second treatment and metastasis after RP. The model was adjusted for age, PSA density, and high genomic score (OncotypeDx GPS>40, Decipher >0.6 or Prolaris>0.8). Results: 1,394 patients were included in the study. Median (IQR) follow-up was 44 (15-91) months. Clinical CAPRA at diagnosis was 6% low, 73% intermediate, and 21% high risk. From 2000 to 2023, the proportion of UIR-PCa patients defined by biopsy GG3 increased 34% to 63%. During the same period, the number of high-risk patients by CAPRA (≥6) increased from 10% to 31%. At RP, the proportion of patients with pathologic GG3 and GG4-5 increased from 22% to 41% and from 7 to 16%, respectively. Seven years following radical prostatectomy (RP), recurrence-free survival was 57% and metastasis-free survival was 92%. Kaplan-Meier analysis demonstrated that 7-year recurrence-free survival after radical prostatectomy was significantly lower for GG3 patients (48%) compared to GG1/GG2 patients (67%), log-rank p<0.01. Meanwhile, 7-year metastasis-free survival after radical prostatectomy was 90% for GG3 patients relative to 94% for GG1/GG2 patients, log-rank p<0.01. Multivariable Cox regression analysis showed a significant increase in the risk of recurrence after RP for GG3 patients compared to GG1/GG2 (HR 1.64, 95% CI 1.32 – 2.05, p<0.01, Table 1), but not for risk of metastasis. Conclusions: The study shows a significant increase in GG3 among UIR-PCa patients over time, and that UIR-PCa defined by GG3 was associated with adverse outcomes after RP. These findings suggest that the current UIR-PCa groupings as defined by the AUA are not created equal and may warrant revision to address an evolving risk profile of UIR-PCa over time. Cox proportional hazards regression for the outcome of recurrence after RP. Effect Parameter Global p Param p HR 95%CI Lower 95%CI Upper Year of diagnosis Per 10 years 0.28 1.01 0.99 1.04 Age at diagnosis Per 10 years 0.44 1.06 0.91 1.24 PSA density Logarithm <.01 1.53 1.29 1.82 Preop genomic Low vs High <.01 <.01 0.64 0.45 0.90 No test vs High <.01 0.49 0.37 0.66 Unfav subgroup GG3 vs GG1/GG2 <.01 1.64 1.32 2.05
CTC and AR-V7 analysis in the ECOG-ACRIN 8153 (CHAARTED2) randomized trial: Abiraterone (Abi) with or without cabazitaxel (Abi-Cabazi) in extensive mCRPC following docetaxel.
181 Background: The CHAARTED2 trial showed improved PFS with Abi-Cabazi over Abi-alone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who previously received docetaxel for metastatic castration-sensitive disease. Here, we evaluated the prognostic and predictive impact of CTC and AR-V7 circulating biomarkers. Methods: The modified AdnaTest (Qiagen) was used to define CTC detection (+ vs –) and AR-V7 detection (+ vs –) at baseline, C5D1, as well as at the time of progression. We first assessed the prognostic value of baseline and C5D1 CTC and AR-V7 status in the two arms. We also assessed the predictive potential of baseline and C5D1 CTC and AR-V7 status to explore if these biomarkers may aid in treatment selection. Logrank test and Cox proportional hazards models were used to assess for associations between clinical outcomes and baseline biomarker status. Landmark analysis was performed to evaluate associations at C5D1. Results: A total of 223 pts were randomized between the two arms. CTC data were evaluable for 94/112 and 94/111 pts in the Abi-alone and Abi-Cabazi arms, respectively. Baseline CTC detection was prognostic for worse PFS in both the Abi-alone (7.1 vs 31.7 months, HR 3.64, P <0.001) and the Abi-Cabazi (9.6 vs 36.9 months, HR 4.13, P <0.001) arms. Likewise, baseline AR-V7 detection portended worse PFS in the Abi-alone (4.1 vs 12.8 months, HR 3.34, P <0.001) and the Abi-Cabazi (6.9 vs 15.1 months, HR 3.17, P <0.001) arms. At C5D1, there was a higher rate of CTC(-) conversion (60 vs 46%) and AR-V7(-) conversion (69 vs 58%) in the Abi-Cabazi arm. CTC(-) and AR-V7(-) status at C5D1 was prognostic of improved PFS in both arms (all P ≤0.02). In terms of predictive impact, PFS was numerically but not statistically longer in the Abi-Cabazi arm in all biomarker groups; the greatest relative PFS benefit to Abi-Cabazi was in the baseline AR-V7(+) group (HR 0.68, 95%CI 0.36–1.3, P =0.2). Similarly, at C5D1, the greatest relative PFS benefit to Abi-Cabazi was in pts remaining AR-V7(+) (HR 0.57, 95%CI 0.15–2.16, P =0.4). Conclusions: Baseline CTC and AR-V7 detection were both prognostic for inferior PFS in both study arms. PFS outcomes were broadly longer in the Abi-Cabazi vs Abi-alone arm in all biomarker groups. The presence of AR-V7 at baseline and at C5D1 was the strongest relative predictor of Abi-Cabazi benefit, but did not meet statistical significance. Clinical trial information: NCT03419234 .